Jastreboff 2023 — Retatrutide Phase 2 Obesity

New England Journal of Medicine·June 26, 2023

Jastreboff AM, et al.

Summary

Retatrutide achieved up to 24.2% weight loss at 48 weeks, exceeding any previously reported anti-obesity medication.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled dose-finding trial

Indication

Obesity

Intervention

Retatrutide (GLP-1/GIP/glucagon triple agonist) vs placebo

Species

Human

Sample Size

338 subjects

Risk of Bias Assessment

Eli Lilly sponsored